跳至主要内容
临床试验/NCT04340700
NCT04340700撤回3 期

Characterization of the Pharmacodynamic Response to Vaped THC

Massachusetts General Hospital0 个研究点开始时间: 2022年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
主要终点
Change in Drug Effects Questionnaire

研究概览

简要总结

This study aims to characterize the pharmacodynamic response to vaped THC in young adult, occasional cannabis users with respect to outcomes such as stimulation and sedative effects, mood, anxiety, and craving, as well as cognitive and objective outcomes such as heart rate and cortisol changes with THC vs placebo.

详细描述

Enrollees will include 120 healthy, weekly or greater MJ users, aged 18-55. The study will be conducted according to a double-blind, placebo-controlled, random order, cross-over design, consisting of one 3-hour screening visit and 2 randomized, approximately 6-hour laboratory sessions. At the latter visits (following confirmation of eligibility), subjects will complete baseline questionnaires and assessments, including a driver simulator test, a blood draw, vitals, and an imaging session using functional near-infrared spectroscopy (fNIRS). Subjects will then vape a first dose (either THC or placebo based on randomization). Vitals and questionnaires will then be administered throughout the visit, at baseline, and at approximately 15, 60, 90, 130, 165, and 210 minutes post initial dose. Subjects will also perform fNIRS testing at baseline, 30, and 180 minutes and driver simulator at baseline, 60, and 90 minutes post initial THC/placebo administration. A drug recognition expert (DRE) will conduct a standard field sobriety test to identify impairment at approximately 130 minutes post dose. Following the initial dose vaped at 0 minutes, standardized reduced doses will be vaped approximately 30, 60, and 90 minutes later. Given the cross-over design of this study, participants will be assigned to receive THC or placebo at the first laboratory visit and will receive the other substance at the second laboratory visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women aged 18-55 years, inclusive.
  • Competent and willing to provide written informed consent.
  • Able to communicate in English language.
  • Regular, at least weekly on average, marijuana use
  • Self-reported ability to abstain from cannabis for 24 hours without withdrawal.

排除标准

  • Any unstable, serious medical illness or cardiovascular disease/events.
  • New or unstable psychiatric symptoms, schizophrenia, or bipolar I disorder.
  • Diabetes, cirrhosis, renal failure, Hepatitis C, or HIV.
  • History of syncope without an identified situational stressor, migraines >1x/month, or head injury with prolonged unconsciousness (> 24 hours).
  • Daily use of benzodiazepines or barbiturates, antihistamines, atropine, scopolamine, or other strong anticholinergic agents.
  • Current pregnancy, lactation or trying to become pregnant (confirmed by urine pregnancy test).
  • History of substance abuse treatment and intent to quit or receiving treatment for cannabis use.
  • Affective disorder in the past month or history of panic attacks.
  • Smoking more than 10 tobacco cigarettes or equivalent e-cigarettes a day.
  • In the opinion of the investigator, not able to safely participate in this study.

研究组 & 干预措施

THC

Experimental

A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.

干预措施: THC or Placebo (Drug)

Placebo

Placebo Comparator

Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.

干预措施: THC or Placebo (Drug)

结局指标

主要结局

Change in Drug Effects Questionnaire

时间窗: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose

This 15-item questionnaire measures drug effects, behavioral/mood states, and craving. Each item is scored from 0-100, and all items are averaged for a total score from 0-100 with higher scores indicating greater drug effect.

Change in Biphasic Alcohol Effects Scale (Modified for THC)

时间窗: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose

This 14-item questionnaire measures stimulation and sedation. The Stimulation subscale scores range from 7-70 with higher scores indicating greater stimulation. The Sedation subscale scores range from 7-70 with higher scores indicating greater sedation.

Change in The Spielberger State Anxiety Inventory

时间窗: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose

This 20-item questionnaire measures state/current anxiety. Scores range from 20-80 with higher scores indicating greater state anxiety.

Change in Driving Simulation Performance on the Divided Attention Task (DAT)

时间窗: Pre-dose, and 60 and 90 minutes post dose

A computer-programmed driving simulator will assess DAT performance using percentage impaired (from 0-100%).

次要结局

  • Change in Functional Near-Infrared Spectroscopy (fNIRS) Brain Signal(Pre-dose, and 30 and 180 minutes post dose)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

A. Eden Evins

Director, Center for Addiction Medicine; Professor in Psychiatry

Massachusetts General Hospital

相似试验